链脲佐菌素、丝裂霉素C和5-氟尿嘧啶用于胰腺癌的II期试验。
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
作者信息
Bukowski R M, Abderhalden R T, Hewlett J S, Weick J K, Groppe C W
出版信息
Cancer Clin Trials. 1980;3(4):321-4.
A phase II study study employing 5-fluorouracil, mitomycin C, and streptozotocin in unresectable pancreatic carcinoma was performed. Seven of 22 patients (32%) responded and 4 of 22 (18%) had stable disease. Median survival of the entire group was 6 months, and of responders 9.5 months. In 13 patients with localized disease, five responses (38%) were seen and median survival was 7.5 months. Toxicity of the regimen was moderate, being predominantly gastrointestinal and renal. The usefulness of this regimen in localized pancreatic cancer should be explored further.
开展了一项II期研究，在不可切除的胰腺癌患者中使用5-氟尿嘧啶、丝裂霉素C和链脲佐菌素。22例患者中有7例（32%）有反应，22例中有4例（18%）病情稳定。整个组的中位生存期为6个月，有反应者为9.5个月。在13例局限性疾病患者中，观察到5例有反应（38%），中位生存期为7.5个月。该方案的毒性为中度，主要是胃肠道和肾脏毒性。该方案在局限性胰腺癌中的有效性应进一步探索。
Zotero 插件